Lead Product(s): mRNA cancer vaccine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: European Commission
Deal Size: $8.3 million Upfront Cash: Undisclosed
Deal Type: Funding March 22, 2021
The grant will be used to accelerate the development of a novel, potentially best-in-class therapeutic mRNA cancer vaccine for treating recurrent/metastatic HPV16+ cancers such as head and neck cancer, cervical cancer, anogenital cancer.